Search
Sotorasib
go.drugbank.com/drugs/DB15569ApprovedInvestigationalSotorasib, also known as AMG-510, is an acrylamide-derived KRAS inhibitor developed by Amgen.
Tisotumab vedotin
go.drugbank.com/drugs/DB16732ApprovedInvestigationalTF is a novel target for cancers, as it is often overexpressed on solid tumours, including cervical cancer, and it is associated with poor clinical outcomes. … [L38429] Tisotumab vedotin-tftv is marketed under the trade name Tivdak as an intravenous injection. On April 29, 2024, tisotumab vedotin was granted full FDA approval.
Thymol
go.drugbank.com/drugs/DB02513ApprovedInvestigationalIt is used as a stabilizer in pharmaceutic preparations. It has been used for its antiseptic, antibacterial, and antifungal actions, and was formerly used as a vermifuge. (Dorland, 28th ed)
Tetrabenazine
go.drugbank.com/drugs/DB04844ApprovedA drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. … It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
Zinc citrate
go.drugbank.com/drugs/DB11154ApprovedInvestigationalIt is available as dietary supplements as a treatment of zinc deficiency and source of zinc, which is an essential trace element.
Mebanazine
go.drugbank.com/drugs/DB09248ApprovedWithdrawnMebanazine, also known as _Actomol_, is a monoamine oxidase inhibitor (MAOI) belonging to the _hydrazine_ class of chemicals. … It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential.
Octamoxin
go.drugbank.com/drugs/DB09249ApprovedWithdrawnThis drug was used in the past as an antidepressant agent in the 1960s, however, has since been discontinued. … Octamoxin, also known as _2-octylhydrazine_, is both an irreversible and nonselective monoamine oxidase enzyme inhibitor (MAOI) of the _hydrazine_ chemical class.
Alirocumab
go.drugbank.com/drugs/DB09302ApprovedInvestigationalAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of
Riltozinameran
go.drugbank.com/drugs/DB17095ApprovedInvestigational[L43917] As of November 2022, it is the primary circulating variant of concern according to the World Health Organization.
Anagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigational[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g.